The U.S. Food and Drug Administration approved the oral GLP-1 medication orforglipron, marketed as Foundayo, in May 2026 [2].

This approval provides a critical transition path for patients who have achieved significant weight loss using injectable drugs but seek a more convenient or affordable maintenance option. By replacing needles with a daily pill, the treatment could increase long-term adherence to obesity management.

Results from a clinical trial were presented this week at the European Congress on Obesity (ECO2026) in Istanbul, Turkey [2, 3]. The study focused on adults with obesity or overweight who had previously used injectable GLP-1 drugs, such as tirzepatide or semaglutide, and then switched to the oral version of orforglipron [1, 2].

Data showed that weight loss achieved with the injectable medications was largely maintained over a one-year period after patients transitioned to the daily pill [3]. In the clinical trial, participants who received the highest dose of orforglipron lost an average of about 25 pounds [4].

Orforglipron is designed to be less costly to manufacture than injectable GLP-1 drugs like Wegovy and Mounjaro [3]. This cost difference, combined with the ease of oral administration, makes it a more accessible alternative for patients who can no longer afford or do not wish to continue with injections [1, 3].

While the medication is already available in the U.S., officials said it may also launch in the United Kingdom [1, 2]. The shift toward oral delivery marks a significant evolution in the treatment of obesity — moving from acute weight loss to sustainable, long-term weight maintenance.

“Weight loss achieved with injectable tirzepatide or semaglutide was largely maintained after switching to daily oral orforglipron over a one-year period.”

The approval of Foundayo addresses a primary challenge in obesity medicine: the 'rebound' weight gain that often occurs when patients stop GLP-1 therapies. By providing a lower-cost, non-invasive maintenance tool, healthcare providers can potentially transition patients from high-intensity weight loss phases to a sustainable maintenance phase, reducing the systemic cost of obesity care and improving patient quality of life.